After years spent building a seemingly slapdash set of medical initiatives, Verily seems to have a game plan.
The Alphabet life sciences spinout is doubling down on the business of evidence generation, trying to build the tools and technical infrastructure that will help pharma and digital health customers run the next generation of clinical trials. It’s an area that Verily and its investors — who just poured $1 billion into the company — are predicting can become a lucrative line of business. And Verily is backing up that bet by filling its ranks with some of the Food and Drug Administration’s top scientific, policy, and legal experts.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
